Tausif Butt - 22 Feb 2022 Form 4 Insider Report for ChemoCentryx, Inc.

Role
EVP, Chief Operating Officer
Signature
/s/ Susan M. Kanaya, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 Feb 2022
Net transactions value
$0
Form type
4
Filing time
24 Feb 2022, 19:56:57 UTC
Previous filing
16 Jun 2021
Next filing
24 Oct 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCXI Restricted Stock Units Award +41,400 41,400 22 Feb 2022 Common Stock 41,400 Direct F1, F2
transaction CCXI Stock Option (right to buy) Award +52,200 52,200 22 Feb 2022 Common Stock 52,200 $29.83 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CCXI common stock.
F2 The restricted stock units awarded on February 22, 2022, vests in four equal installments on January 1, 2023, January 1, 2024, January 1, 2025, and January 1, 2026, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date.
F3 The option was granted on February 22, 2022, and 25% of the total number of shares of common stock subject to the option vests on January 1, 2023, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date.
F4 Not applicable.